Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,001 public trials 2,038 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents

NCT02745769

Conditions
Advanced Cancer, Colonic Diseases, Colorectal Cancer, +20 more
Locations
  • UAB Comprehensive Cancer Center Birmingham, Alabama, United States
  • University of Texas MD Anderson Cancer Center Houston, Texas, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Lyon, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Marseille, France
View Trial Details
Completed

First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02

NCT01790737

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Kuopio University Hospital Kuopio, Northern Savonia, Finland
  • Tampere University Hospital Tampere, Pirkanmaa, Finland
  • Kanta-Häme Central Hospital Hämeenlinna, Finland
  • Helsinki University Hospital Helsinki, Finland
View Trial Details
Completed

Alemtuzumab and CHOP in T-cell Lymphoma

NCT00646854

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • AKH Linz Linz, Austria
  • Krankenhaus der Elisabethinen Linz, Austria
  • Center for Clinical Cancer and Immunology Trials Salzburg, Austria
  • Hanusch Krankenhaus Vienna, Austria
View all 59 locations
View Trial Details
Completed

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

NCT02549651

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Research Site La Jolla, California, United States
  • Research Site Baltimore, Maryland, United States
  • Research Site Albuquerque, New Mexico, United States
  • Research Site Durham, North Carolina, United States
View all 13 locations
View Trial Details

Related conditions